Mikkael A. Sekeres, MD, MS, Sylvester Comprehensive Cancer Center

Mikkael A. Sekeres, MD, is a professor of medicine and chief of the Division of Hematology, in the Leukemia Section, at the Sylvester Comprehensive Cancer Center, University of Miami Health System.

Articles

Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL Management

March 4th 2024

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

Future Directions in MDS

September 9th 2021

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, discuss future directions and novel therapeutic agents for patients with MDS.

MDS Treatment Selection: Impact of QoL

September 9th 2021

Drs Madanat and Sekeres comment on the importance of quality of life and patient perspective in the selection of MDS treatment.

Unmet Needs in MDS

September 2nd 2021

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, highlight unmet needs in the treatment of patients with high-risk MDS.

MDS: Clinical Primary Endpoints

September 2nd 2021

Experts in the treatment of MDS explore clinically meaningful treatment endpoints, including complete responses, bone marrow complete responses, and overall survival outcomes in MDS.

MDS Treatment: Patient Considerations

August 26th 2021

Drs Madanat and Sekeres discuss specific patient characteristics affecting selection of treatment for MDS.

MDS Treatment-Related Toxicity and AEs

August 26th 2021

Yazan Madanat, MD, explores toxicity and adverse events impacting treatment selection for patients with MDS.

High-Risk MDS: Clinical Efficacy Data

August 19th 2021

Mikkael A. Sekeres, MD, discusses his approach to treatment in patients with high-risk MDS incorporating efficacious clinical trial data.

Clinical Implications of High-Risk MDS

August 19th 2021

Experts in the treatment of MDS discuss the clinical implications and treatment selection for patients with high-risk MDS.

Dr. Sekeres on the Goal of Transfusion Independence in Higher-Risk MDS

August 12th 2021

Mikkael A. Sekeres, MD, discusses the goal of transfusion independence in higher-risk myelodysplastic syndromes.

High-Risk MDS: Prognostic and Predictive Factors

August 12th 2021

Mikkael A. Sekeres, MD, explores prognostic and predictive factors inherent to high-risk MDS, including age and molecular abnormalities.

MDS: Risk Assessment Tools

August 12th 2021

Yazan Madanat, MD, discusses available MDS risk assessment tools and provides insight into his preferred clinical assessment methods.

Clinical Considerations in the Diagnosis of MDS

August 5th 2021

Drs Madanat and Sekeres comment on the various risk stratification factors and prognostic criteria used in the classification of MDS disease.

Classification of Myelodysplastic Syndrome

August 5th 2021

Yazan Madanat, M.D and Mikkael A. Sekeres, M.D. discuss considerations in the classification of myelodysplastic syndrome taking into account disease heterogeneity.